Learn about Lutetium-177 PSMA Therapy in Germany, an advanced targeted treatment for prostate cancer performed under world-class safety and care standards.

Lutetium-177 PSMA Therapy in Germany

Prostate cancer is one of the most frequently diagnosed cancers in men, and when it progresses to an advanced or metastatic stage, treatment becomes increasingly complex. Many patients reach a point where conventional therapies such as surgery or chemotherapy are no longer effective. This is where Lutetium-177 PSMA Therapy offers new possibilities. This therapy uses a radioactive isotope, Lutetium-177, linked to a molecule that binds specifically to Prostate-Specific Membrane Antigen (PSMA) receptors found on prostate cancer cells. Once administered, it delivers focused radiation directly inside the tumor, effectively damaging cancer cells while preserving surrounding healthy tissue.

Lutetium-177 PSMA Therapy in Germany represents one of the most advanced developments in managing metastatic prostate cancer. In Germany, this therapy is performed in specialized nuclear medicine centers under strict EU safety and regulatory standards with precision imaging and patient-focused care. TIG (Treatment in Germany) provides seamless coordination and complete logistic arrangements for patients, including travel, lodging, and medical visa for international patients (if required).

What Makes Lutetium-177 PSMA Therapy Unique

Lutetium-177 PSMA Therapy works by attaching a radioactive isotope, Lutetium-177, to a molecule that targets PSMA receptors on prostate cancer cells. Once the compound reaches these receptors, it delivers controlled beta radiation, destroying cancer cells internally while preserving healthy tissue nearby.

The radiation range is only about two millimeters, which makes it ideal for treating micro-metastases with accuracy. German specialists perform individualized dosimetry calculations for every patient, ensuring that the radiation dose is both effective and safe. This combination of science, precision, and ethical medical care has made German healthcare centers leaders in this field.

How Lutetium-177 PSMA Therapy Works in Germany

Initial Assessment. Specialist review your medical history, prior treatments, and PSA levels. A PSMA PET/CT scan confirms PSMA expression on cancer cells, ensuring the therapy targets tumors effectively. This step also evaluates kidney function to minimize risks.

Pre-Treatment Preparation. Before infusion, you receive amino acids to protect your kidneys from radiation. The Lutetium-177 PSMA-617 dose is calculated based on your weight and tumor burden for optimal results.

Infusion Procedure. In a shielded room, the therapy is administered intravenously over 30-60 minutes. The process is painless, with nursing staff ensuring your comfort throughout.

Post-Infusion Monitoring. You stay for 1-2 hours for observation, receiving fluids to support hydration. Staff check for rare immediate reactions, ensuring safety.

Discharge and Follow-Up. You leave the same day with instructions to drink plenty of fluids and avoid close contact due to mild radiation. Follow-up scans and PSA tests occur 8-12 weeks later, with specialist reviewing results to plan further cycles.

Patients generally tolerate therapy well, and most resume daily activities within 48 hours.

Who Can Receive Lutetium-177 PSMA Therapy in Germany

1This therapy is suitable for patients with PSMA-positive metastatic or recurrent prostate cancer, especially when other treatments such as chemotherapy have stopped being effective.

Ideal candidates include patients who have:

PSMA-positive metastases in lymph nodes or bones

Progressive disease despite previous therapies

Inoperable or resistant prostate cancer

Before starting treatment, German specialists conduct comprehensive diagnostics to ensure eligibility and tailor the approach to each patient’s individual needs.

Benefits of Lutetium-177 PSMA Therapy

This therapy provides highly localized cancer control by focusing radiation only on PSMA-expressing cells. The key advantages include:

Noticeable reduction in PSA levels after several cycles

Shrinkage of tumor lesions visible on imaging

Relief from bone pain and improved quality of life

Minimal side effects compared to systemic chemotherapy

While results depend on tumor size, disease stage, and the patient’s overall health, studies and clinical practice show that targeted radioligand therapy can significantly slow disease progression. In Germany, outcomes are closely monitored through detailed imaging and laboratory testing to ensure continued safety and effectiveness.

Diagnostics and Imaging before Therapy in Germany

Accurate diagnostics form the foundation of successful treatment. German clinics use:

PSMA PET/CT scans for detailed visualization of tumor sites

MRI and CT imaging to measure tumor volume

PSA blood testing for biochemical monitoring

Kidney and liver function assessments to confirm treatment readiness

All diagnostics are performed according to German and EU regulatory standards. The results guide specialists in planning an individualized treatment plan, ensuring precision and patient safety throughout the process.

Treatment Schedule and Duration in Germany

The number of Lutetium-177 PSMA Therapy sessions varies depending on each patient’s clinical condition, imaging findings, and treatment goals. German specialists determine the optimal schedule after carefully reviewing the extent of disease, organ function, and response to earlier therapy. Each treatment plan is customized to deliver the most effective dose while maintaining the highest level of safety and precision, ensuring that care remains individualized rather than standardized. 

Leading Expert Offering PSMA Therapy in Germany

Prof. Dr. Stefan Dresel, a distinguished specialist in nuclear medicine, leads one of Germany’s top programs for Lutetium-177 PSMA Therapy in Germany. His team’s commitment to research, innovation, and personalized patient protocols has positioned Germany among the global leaders in nuclear-medicine oncology.

Cost of Lutetium-177 PSMA Therapy in Germany

The cost of Lutetium 177 PSMA Therapy in Germany is €19,000, covering consultations, PSMA-PET/CT imaging, dose preparation, and administration. This cost reflects Germany’s high-quality infrastructure and expertise. TIG (Treatment in Germany) supports international patients at www.treatmentingermany.de , managing coordination and complete logistic arrangements, including travel, lodging, and medical visa for international patients (if required).

Benefits of Lutetium 177 PSMA Therapy in Germany

International patients choose cancer treatment in Germany for:

EU-approved Lutetium 177 PSMA Therapy with high safety standards.

Minimal side effects and rapid recovery within days.

Comprehensive support via TIG (Treatment in Germany) and medical visa for international patients (if required).

Precision oncology for targeted tumour reduction.

🌍Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained:

Frequently Asked Questions

What is Lutetium 177 PSMA Therapy in Germany used for?
It targets PSMA-expressing cancer cells, reducing cancer symptoms like pain, improving patient outcomes via precision oncology.

Is Lutetium 177 PSMA Therapy safe?
Yes, it’s safe, with minimal side effects like fatigue.

What types of prostate cancer can be treated with Lutetium-177 PSMA therapy?
Lutetium-177 PSMA therapy in Germany is used for advanced, metastatic, or treatment-resistant prostate cancer, offering precise targeted care under expert supervision.

Are there any side effects of Lutetium-177 PSMA therapy?
Most patients tolerate Lutetium-177 PSMA therapy well, with only mild effects like fatigue or dry mouth carefully managed through ongoing monitoring and patient care in German healthcare centers.

What is the cost of Lutetium 177 PSMA Therapy in Germany?
It costs €19,000, covering consultations, imaging, and administration, led by Prof. Dr. Stefan Dresel.

Is Lutetium 177 PSMA Therapy FDA-approved?
No, it’s not FDA-approved in the USA but follows EU standards, ensuring safety for international patients.

How do international patients access Lutetium 177 PSMA Therapy?
Contact TIG (Treatment in Germany) at www.treatmentingermany.de  for coordination and complete logistic arrangements for international patients.

What cancer detection tests support cancer diagnosis for Lutetium 177 PSMA Therapy?
PSMA-PET/CT and PSA tests ensure accurate diagnosis across cancer stages.

How many Lutetium 177 PSMA Therapy sessions are needed?
Sessions vary based on tumour response, monitored by cancer detection tests.

What is the success rate of Lutetium 177 PSMA Therapy?
The success rate of Lutetium 177 PSMA Therapy varies depending on the type and stage of the cancer, tumor size, and overall patient condition.

Who is the best cancer specialist in Germany?
Germany has many highly experienced oncologists and specialized cancer centers known for advanced diagnostics and personalized treatment approaches. The “best” cancer specialist depends on the specific cancer type and treatment needs. Some of the most recognized cancer experts include professors working at leading hospitals such as Charité University Hospital (Berlin), University Hospital Heidelberg, University Hospital Munich (LMU), and Frankfurt University Hospital.